Voyager Therapeutics
VYGR
59 hedge funds and large institutions have $51.3M invested in Voyager Therapeutics in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 24 closing their positions.
144% more call options, than puts
Call options by funds: $899K | Put options by funds: $369K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8.96% less ownership
Funds ownership: 58.63% → 49.67% (-9%)
12% less capital invested
Capital invested by funds: $58.6M → $51.3M (-$7.32M)
14% less funds holding
Funds holding: 69 → 59 (-10)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.51M |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$1.02M |
| 4 |
D.E. Shaw & Co
New York
|
+$1M |
| 5 |
Millennium Management
New York
|
+$511K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$9.77M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.12M |
| 3 |
BlackRock
New York
|
-$1.59M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.15M |
| 5 |
JP Morgan Chase
New York
|
-$919K |
VYGR Hedge Fund Activity: Q4 2021 in Review
59 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2021, worth a combined $51.3M — down 12% from $58.6M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of VYGR and 14 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was EcoR1 Capital, adding an estimated $10.6M. The largest seller was Armistice Capital, exiting entirely with an estimated $9.77M sold.
- 59 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2021, down from 69 in Q3 2021.
- Funds reported $51.3M of Voyager Therapeutics stock for Q4 2021, down 12% quarter-over-quarter.
- 14 funds opened new Voyager Therapeutics positions in Q4 2021 and 24 closed out, a net change of -10 holders.
- The largest Voyager Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $10.6M added.
- The largest Voyager Therapeutics seller in Q4 2021 was Armistice Capital, an estimated $9.77M sold.
Based on aggregated 13F filings for Q4 2021.